- Home
- SXTC vs BIVI Comparison
SXTC vs BIVI Comparison
Compare SXTC & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SXTC
- BIVI
- Stock Information
- Founded
- SXTC 2005
- BIVI 2013
- Country
- SXTC China
- BIVI United States
- Employees
- SXTC N/A
- BIVI N/A
- Industry
- SXTC Biotechnology: Pharmaceutical Preparations
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- SXTC Health Care
- BIVI Health Care
- Exchange
- SXTC Nasdaq
- BIVI Nasdaq
- Market Cap
- SXTC 14.0M
- BIVI 15.1M
- IPO Year
- SXTC 2019
- BIVI N/A
- Fundamental
- Price
- SXTC $2.01
- BIVI $1.23
- Analyst Decision
- SXTC
- BIVI Strong Buy
- Analyst Count
- SXTC 0
- BIVI 1
- Target Price
- SXTC N/A
- BIVI $30.00
- AVG Volume (30 Days)
- SXTC 12.0M
- BIVI 757.2K
- Earning Date
- SXTC 01-01-0001
- BIVI 05-13-2025
- Dividend Yield
- SXTC N/A
- BIVI N/A
- EPS Growth
- SXTC N/A
- BIVI N/A
- EPS
- SXTC 20.77
- BIVI N/A
- Revenue
- SXTC $1,818,404.00
- BIVI N/A
- Revenue This Year
- SXTC N/A
- BIVI N/A
- Revenue Next Year
- SXTC N/A
- BIVI N/A
- P/E Ratio
- SXTC $0.09
- BIVI N/A
- Revenue Growth
- SXTC 6.78
- BIVI N/A
- 52 Week Low
- SXTC $0.30
- BIVI $0.62
- 52 Week High
- SXTC $5.70
- BIVI $7.50
- Technical
- Relative Strength Index (RSI)
- SXTC 48.57
- BIVI 63.09
- Support Level
- SXTC $0.95
- BIVI $1.04
- Resistance Level
- SXTC $2.45
- BIVI $1.29
- Average True Range (ATR)
- SXTC 0.69
- BIVI 0.13
- MACD
- SXTC 0.01
- BIVI 0.06
- Stochastic Oscillator
- SXTC 46.70
- BIVI 83.64
About SXTC China SXT Pharmaceuticals Inc.
China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.